CDRD and TRIUMF Announce Collaboration to Revolutionize the Fight Against Cancer with Targeted Alpha Therapy

April 2, 2019
CDRD

Vancouver, BC and Ottawa, ON – April 2, 2019: CDRD, Canada’s life sciences venture, TRIUMF, the country’s national particle accelerator centre, and TRIUMF Innovations, the centre’s commercialization arm have joined forces to advance and commercialize promising research in the field of novel radiopharmaceuticals. Speaking at the 11th International Symposium on Targeted Alpha Therapy (TAT 11) … Continue reading CDRD and TRIUMF Announce Collaboration to Revolutionize the Fight Against Cancer with Targeted Alpha Therapy

Natalie Dakers Receives 2019 Milton Wong Award for Leadership

Accel-Rx Health Sciences Accelerator

Accel-Rx CEO Recognized for Contributions to Life Science Sector April 2, 2019 VANCOUVER, BC – Accel-Rx, Canada’s national health sciences accelerator, is pleased to announce that President and Chief Executive Officer, Natalie Dakers has been awarded the 2019 Milton Wong Award for Leadership. The award recognizes and celebrates an individual working in the life sciences … Continue reading Natalie Dakers Receives 2019 Milton Wong Award for Leadership

Evening of Inspiration and Enlightenment for Women in Health Sciences

March 28, 2019
Novateur Ventures

Importance of Women’s Leadership in Life Sciences by Ali Ardakani | Mar 25, 2019 | Health Science, Leadership, Science, Technology, Women | It wasn’t very long ago when, at the JP Morgan Healthcare Conference, presenters named Michael outnumbered female CEOs giving company presentations [1]. Of the presenters, there were 22 men named Michael, overshadowing the total number of 20 female CEOs. With 4 out of … Continue reading Evening of Inspiration and Enlightenment for Women in Health Sciences

Phoenix Molecular Designs Appoints Magda Marquet, Ph.D. to its Board of Directors

March 22, 2019
Phoenix MD

VANCOUVER, British Columbia and SAN DIEGO, March 21, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced today the appointment of Magda Marquet, Ph.D., to its Board of Directors. Dr. Marquet brings a wealth of entrepreneurial and biotech experience to PhoenixMD, having founded, led, and commercialized many highly successful companies, … Continue reading Phoenix Molecular Designs Appoints Magda Marquet, Ph.D. to its Board of Directors

TRIUMF receives historic investment in 2019 federal budget

March 20, 2019
TRIUMF Innovations

March 19, 2019, VANCOUVER, BC – Today, the Government of Canada reaffirmed its longstanding support for TRIUMF with the announcement of a $292.7M investment over five years to support laboratory operations. This funding represents the largest single investment in TRIUMF to date. It comes in response to the bold vision presented in TRIUMF’s recently publishedFive-Year Plan 2020-2025. Details of the new funding were included in the 2019 federal budget, which was … Continue reading TRIUMF receives historic investment in 2019 federal budget

New Scientific Study Finds Stevia Sweeteners Have No Impact on Digestive System Bacteria

March 14, 2019
Biopharmaceutical Research Inc. (BRI)

Chicago, Illinois March 4, 2019 – PureCircle, in collaboration with Biopharmaceutical Research Inc. (BRI), announces the results of important new scientific research which found that the company’s new generation stevia leaf sweeteners such as Reb D and Reb M have no impact on the system of bacteria in the human digestive system; that bacteria system … Continue reading New Scientific Study Finds Stevia Sweeteners Have No Impact on Digestive System Bacteria

Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives

March 7, 2019
Arbutus Biopharma Corp.

– Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg – Ongoing analyses of AB-452, a novel orally-available RNA destabilizer, with a go/no go decision expected in the second half of the year – Ongoing characterization of the RNA destabilizer mechanism and several novel compounds in … Continue reading Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives

Onestep Laboratories to develop a stable formula for Chlorine Analysis

Onestep Laboratories

Vancouver, BC – March 6, 2019 – Onestep Laboratories, a B.C. based biotech company that specializes in developing and producing raw material for immunoassay and other assays, has successfully developed a stable formula for chlorine analysis. Chlorine has been used for public health for more than a century. Today, more than 80,000 tons of chlorine … Continue reading Onestep Laboratories to develop a stable formula for Chlorine Analysis

Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update

March 6, 2019
XENON PHARMACEUTICALS INC.

Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 Global XEN1101 Phase 2b Clinical Trial Underway with Data Anticipated in Second Half of 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 06, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, … Continue reading Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update

Arbutus to Present at Cowen Health Care Conference

March 4, 2019
Arbutus Biopharma Corp.

WARMINSTER, Pa., March 04, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark Murray, Arbutus’ President and CEO, will present a corporate overview and business update at the Cowen Health Care Conference on Monday, March 11, 2019 at 2:50 PM ESTin Boston. A live webcast of the presentation can be accessed through … Continue reading Arbutus to Present at Cowen Health Care Conference